Insight Molecular Diagnostics (IMDX) Other Accumulated Expenses (2016 - 2026)

Insight Molecular Diagnostics has reported Other Accumulated Expenses for 9 years, with the latest figure at $1.1 million in Q1 2026.

• Quarterly Other Accumulated Expenses changed 0.0% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (changed 0.0% YoY) and the FY2025 annual result came in at $1.1 million, up 74.92% from the prior year.
• Other Accumulated Expenses steadied at $1.1 million in Q1 2026 per IMDX's latest filing, from $1.1 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $2.0 million in Q4 2022 and troughed at $638000.0 in Q4 2024.
• A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses slumped 44.81% in 2023, then jumped 74.92% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $2.0 million in 2022, then plunged by 44.81% to $1.1 million in 2023, then tumbled by 42.83% to $638000.0 in 2024, then surged by 74.92% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.1 million, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.